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Obstetric thromboprophylaxis is diﬃcult. Since 10 years Swedish obstetricians have used a combined risk estimation model
and recommendations concerning to whom, at what dose, when, and for how long thromboprophylaxis is to be administrated
based on a weighted risk score. In this paper we describe the background and validation of the Swedish guidelines for obstetric
thromboprophylaxis in women with moderate-high risk of VTE, that is, at similar or higher risk as the antepartum risk among
women with history of thrombosis.The risk score is based on major risk factors (i.e., 5-fold increased risk of thromboembolism).
We present data on the eﬃcacy of the model, the cost-eﬀectiveness, and the lifestyle advice that is given. We believe that the
Swedish guidelines forobstetric thromboprophylaxisaid cliniciansin providing women atincreased risk ofVTE with eﬀective and
appropriate thromboprophylaxis, thus avoiding both over- and under-treatment.
1.Introduction
The incidence of obstetric venous thromboembolism (VTE)
in the Nordic countries is estimated at 10 to 13 cases per
10000 pregnancies, half of them diagnosed during the ﬁrst
six weeks after birth [1, 2]. VTE is one of the most common
causes of maternal death [3, 4] and leads to morbidity in the
form of postthrombotic syndrome in up to 50–60% [5, 6].
Several factors are known to increase the risk of obstetric
VTE, such as personal or family history of VTE, thrombo-
philia, older age, high body mass index (BMI), immobiliza-
tion, surgery, smoking, nulliparity, and cancer [1, 2].
Thromboprophylaxis during pregnancy usually consists
of daily subcutaneous injections of low molecular weight
heparin (LMWH), in combination with compression stock-
ings [7–10]. There are several recommendations concerning
how toidentify women athigh risk ofVTE during pregnancy
and the puerperium. Some of them divide women into low-
medium and high-risk groups [7, 8] and others are based
on weighted risk scores [9, 10]. Risk assessment and man-
agement of obstetric thromboprophylaxis diﬀer in diﬀerent
countries.
The aim of this paper is to describe the background and
validation of the Swedish guidelines for obstetric thrombo-
prophylaxis in women with moderate-high risk of VTE. A
weighted risk score for estimation of obstetric VTE risk has
been used in Swedenfor around 10 years. Recommendations
concerning to whom, at what dose, when, and for how long
thromboprophylaxis is to be administered are based on this
risk score. A small number of special cases (women with
antithrombin deﬁciency, antiphospholipid syndrome (APS)
with prior VTE or prior multiple VTE, as well as those on
chronic warfarin treatment) cannot be managed according
to the risk score. These women are estimated to be at very
high, that is, 15% or higher, risk of obstetric VTE. They
are recommended “two-dose” thromboprophylaxis, which is
not included in this paper. Thromboprophylaxis in relation
to legal abortion, miscarriage, or ectopic pregnancy is also
excluded from this paper.
2.Methods
The available literature from 1996 to 2000 on risk factors
for obstetric VTE was reviewed. Two diﬀerent risk models2 Advances in Hematology
Table 1: Risk factors and their odds ratios (ORs) f¨ or VTE (1,2).
Prevalence (%) Pregnancy OR Postpartum OR
Overweight (BMI > 28)1
>28BMI 12.8 5 5
Familial thrombosis (ﬁrst-degree relatives)
yes 5.1 5 5
Age
<20 2.5 1.0 2.5
≥20–<35 85.2 1.0 1
≥35 12.4 1.0 1.2
Smoking
yes 21.0 1.2 1.2
Parity
Primapara 41.3 2.3 1.1
1 birth 35.4 1 1
2 births 15.8 1.3 1.7
>2 births 7.3 2.6 1.8
Preeclampsia
Yes 2.0 3–5
Cesarean section
Yes 11.0 4.9
FV Leiden
Noncarrier 89.1 1 1
Heterozygotes 10.6 5 5
Homozygotes 0.3 25–100 25–100
Protein S or protein C deﬁciency 0.1 5–25 5–25
Prothrombin gene mutation 2.0 5 5
Hyperhomocysteinemia 2–5 2–5
1BMI > mean + 1SD in early pregnancy is regarded as overweight.
were constructed, one a weighted risk score based on major
risk factors associated with a ﬁve-fold increased risk or a
multiple thereof [11, 12], and the other an individualized
computerized risk assessment using and including estimates
ofthe absoluterisk [11].Hem-ARG, the Swedish Association
of Obstetricians and Gynecologists (SFOG) reference and
working group on hemostatic disturbances in obstetrics and
gynecology, chosed the weighted risk score model. Swedish
guidelines based on this model were published in 2004 [12],
and established as a National Guideline by SFOG in 2009.
The guidelines were revised in 2010-2011, resulting in the
version presented here.
2.1. Risk Assessment of Obstetric VTE. To facilitate the assess-
ment of VTE risk during pregnancy and the puerperium, a
scoring system was created by adding the weight of various
riskfactors(Table 1)forobstetricVTE[1].Anapproximately
ﬁve-fold increased risk of VTE during pregnancy, shown by
the odds ratio (OR) for a number of risk factors for VTE,
yields one risk score point (Table 2). Three conditions, cesa-
rean section (CS), preeclampsia, and abruptio placentae, are
only considered to be risk factors during the puerperium.
Since all risk factors cannot be included in an algorithm, the
variable “other major risk factor” is included (Table 2)a n d
may be used, according to the clinician’s decision, in cases
of malignancy, extreme obesity, and so forth. The woman’s
risk score is calculated as the sum of the points. Women with
risk score 1 are at a ﬁve-fold increased risk, risk score 2 (two
variables with 1 point or one variable with 2 points) are at
a 25-fold increased risk and risk score 3 entails a 125-fold
increased risk, and so forth, compared to risk score 0, which
means no increased risk (Table 2). Women with a previous
VTE or APS without VTE are given 4 risk points, regardless
of other risk factors. The total risk score is the basis for
determining when, how, and at what dose thromboprophy-
laxis should be administered (Table 3).
During pregnancy it is mainly women with prior VTE
that reach the risk score levelforthromboprophylaxis. A het-
erozygous carrier of Factor V Leiden (FVL) without any
other risk factors has 1 risk point and would not be recom-
mended ante- or postpartum prophylaxis. However, if she
also has ﬁrst-degree heredity for VTE, one more risk point
is added, resulting in a risk score of 2, leading to a rec-
ommended one week of postpartum thromboprophylaxis.
If she also undergoes CS, she is given 3 risk points (FVL,
heredity,andCS),resultinginarisk scoreof3,andshewould
be recommended six weeks of postpartum thromboprophy-
laxis.Advances in Hematology 3
Table 2: Risk points, each corresponding to a ﬁve-fold increased risk, are added, yielding a risk score.
1p o i n t 2p o i n t s 3p o i n t s >4p o i n t s 5 Very high risk6
Heterozygote FV Leiden Prot S deﬁciency Homo FV Leiden Prior VTE Mechanical heart prosthesis
Heterozygote FII mut Prot C deﬁciency Homo FII mut APS without VTE7 Chronic warfarin prophylaxis
Overweight1 Immobilization4 Antithrombin deﬁciency
Cesarean Section Recurrent VTE
Heredity for VTE2 APS with VTE7
Age >40 years
Preeclampsia
Hyperhomocysteinemia3
Abruptio placenta
Inﬂammatory bowel disease
Other major riskfactor
Homo: Homozygote, mut: mutation, VTE: venous thrombembolism.
APS: Antiphospholipidsyndrome, Prot: protein, FV: faktor V, FII: factor II (prothrombin).
1Overweight = (BMI >28 in early pregnancy).
2VTE in ﬁrst-degree relative <60 years of age.
3Homocysteine >8 µmol/L in pregnancy.
4During cast treatment for fracture or strict bed rest short-term thromboprophylaxis is recommended.
5Women with prior VTE or APS without VTE have risk score 4 independent of other risk factors.
6Women in this group are classiﬁed as “very high risk” and are not scored.
7Women with APS are recommended low dose (75mg) acetylsalicylicacid in addition to LMWH.
The risk score is formed by adding each point to a score between 0 and maximum 4 (for >4 points).
Table 3: Managementbased on risk score (the sum of riskpoints in Table 1).
Risk score
0 No thromboprophylaxis
1 No thromboprophylaxis
2 Short-term LMWH thromboprohylaxis after delivery (7 days)∗ or during immobilization
3 6 weeks of LMWH thromboprophylaxis after delivery∗
≥4 Antepartum thromboprophylaxis, and at least 6 weeks postpartum∗∗
“Very high risk” High-dose antepartum prophylaxis and at least 12 weeks of postpartum prophylaxis∗∗∗
∗Initiated 4 hours after delivery.
∗∗Women with history of VTE initiate thromboprophylaxis in early pregnancy.
∗∗∗Thromboprophylaxis is initiated as early as possible and sometimes before pregnancy. Only women with antithrombin deﬁciency, chronic warfarin
prophylaxis, recurrent VTE, antiphospholipidsyndrome with VTE, and those with mechanical heart prosthesis are included in this group.
The model also takes into account the variation in risk
during pregnancy and the puerperium, that is, about a ﬁve-
fold higher risk postpartum, at its highest during the ﬁrst
week after delivery [2, 13]. This could make diﬀerent du-
rations of postpartum thromboprophylaxis possible, for
example, one week (risk score 2), six weeks (risk score 3 or
4),orthreemonths“veryhighrisk”(Table 3).Someweakbut
signiﬁcant risk factors are not considered in this model, such
as smoking, blood group other than O, multiple gestation,
varicose veins, parity, and acute CS (as compared to elective
CS).Severaloftheseriskfactorshavebeentakenintoaccount
in another model [11]( Table 1).
3.Recommendations
As is evident from Table 2, LMWH thromboprophylaxis is
recommended at a risk level corresponding to the antenatal
risk of women with one prior VTE. This risk levelcan also be
attained by the simultaneous existence of several risk factors
in a woman with no history of VTE. The diﬀerences in
ante-andpostpartumrisk(postpartumriskisaboutﬁve-fold
higher) and the quickly decreasing risk after the ﬁrst post-
partum week are taken into account in the scoring system. In
the following, we will present “normal-dose” thrombopro-
phylaxis, as recommended for women at moderate-high risk
of VTE during pregnancy.
LMWH thromboprophylaxis is recommended as soon as
pregnancy is conﬁrmed in women with previous VTE or a
risk score of at least 4 points. If thromboprophylaxis is only
indicated postpartum, it is initiated about four hours after
uncomplicated childbirth and no laboratory testing is re-
quired. In case of bleeding complications, an individual
assessment is recommended. During pregnancy and after
vaginal delivery, LMWH is usually injected in the abdominal
wall. Pharmacological treatment is always combined with
compression stockings, grade 1 knee socks that are used as4 Advances in Hematology
Table 4: Distribution of risk score∗ in a pregnant population, at delivery [17], among women with postpartum VTE, or postpartum
pulmonary embolism [19].
Riskscore∗
Reference group during Reference group at Post partum VTE Post partum pulmonary
pregnancy delivery group embolism
(n = 2384) (n = 2384) (n = 37) (n = 11)
n % n % n % n %
0 1940 81.4 1758 74.0 10 27.0 2 18.2
1 414 17.4 515 22.0 9 24.3 1 9.1
2 22 0.9 96 4.0 10 27.0 4 36.4
3 0 0 7 0.3 3 8.1 2 18.2
≥4 8 0.3 8 0.3 5 13.5 1 9.1
∗Risk score based on anamnestic variables.
early as possible during pregnancy and continued at least 12
weeks postpartum. In the case of postthrombotic syndrome,
grade 2 stockings are recommended.
3.1. “Normal Dose” Thromboprophylaxis during Pregnancy.
Before the initiation of thromboprophylaxis, APTT, PT
(INR), and platelet count are checked. Platelet count is re-
peated after two weeks of thromboprophylaxis to rule out
heparin-induced thrombocytopenia (HIT). LMWH throm-
boprophylaxisis administered at the“normal dose” (Table 5)
once daily throughout pregnancy without monitoring anti-
coagulant eﬀect to women with a VTE risk score of at least
4a n db o d yw e i g h t≤90kg (in early pregnancy). A higher
initiation dose is recommended (Table 5)f o rw o m e nw i t ha
body weight exceeding 90kg; they should also test anti-FXa
activity three hours postinjection, about 2 weeks after the
initiation or dose change. An anti-FXa activity between 0.20
and 0.45U/mL is the goal. If necessary, the dose is adjusted,
reduced, or increased by half the “normal dose.” If the
initialanti-FXaactivity isappropriate,nofurtherveriﬁcation
is required, in the absence of abnormal weight gain or
obstetric complications. The recommendations of diﬀerent
doses according to weight are based on pharmacokinetic
studies and clinical experience of recurrences [14, 15].
Inadditiontotheusualvisitstothemidwife,womenwith
prior VTE are usually scheduled for two extra visits to an
obstetrician: one at the beginning of pregnancy for planning
and initiation of thromboprophylaxis and one at about 34
weeks of gestation for planning of thromboprophylaxis in
relation to delivery; lifestyle information is also given (see
below).
Short-term thromboprophylaxis is recommended during
situations entailing temporary risk increases (e.g., fractures
with casts, strict bed rest). Women with ovarian hyperstimu-
lation syndrome (OHSS) after in vitro fertilization are given
“normal-dose” thromboprophylaxis during hospitalization
and for six weeks after leaving hospital.
3.2. “Normal Dose” Thromboprophylaxis during Delivery and
Postpartum. On arrival at the maternity ward, APTT, PT
(INR),and platelet countare assessed and thetime ofthelast
LMWH injection is recorded. Spontaneous vaginal delivery
is usually planned. LMWH is discontinued during active
laborandthenext injectionisadministered aboutfourhours
afterbirth.Thromboprophylaxisisinitiatedaboutfourhours
after CS in cases with risk score >2. The ﬁrst week after
CS, the injection is given in the thigh in order to avoid
hematomas in the abdominal wall.
Afterdelivery,thesame doseofLMWHisgivenasduring
pregnancy and the thromboprophylaxis is continued for one
(risk score 2) or six weeks (risk score 3 or 4), depending
on the risk score. After complicated delivery, individualized
initiation of thromboprophylaxis is mandatory. Cessation of
bleeding must always take precedence before thrombopro-
phylaxis, but it is important to start thromboprophylaxis
again as soon as possible after the condition is stabi-
lized. LMWH thromboprophylaxis is usually recommended
postpartum but sometimes the women want to change to
warfarin in order to avoid injections. Warfarin thrombo-
prophylaxis makes it even more important to be vigilant
for bleeding complications postpartum if abnormal bleeding
occurs. The eﬀect of warfarin may vary considerably; higher
doses and more monitoring are necessary in the immediate
postpartum period, compared to non-pregnant conditions
[16]. If warfarin is being considered for women with protein
C or S deﬁciency, it is initiated at a lower dose than normal
and LMWH administration should continue simultaneously
for at least one week.
4.Discussion
4.1. Thromboprophylaxis at Diﬀerent Risk Levels. The risk
score isa clinical aid foravoidingover- and under-treatment.
The proportion of women with risk score 2 in a pregnant
population is 0.9% during pregnancy and 4.0% postpartum
(Table 4)[ 17]. The reason for this discrepancy is that CS,
preeclampsia, and abruptio placentae only raise the risk of
VTE postpartum (Table 2). If the risk score is the basis
for clinical management, less than 5% of all women will
receive LMWH thromboprophylaxis, that is, less than 0.5%
of the population will receive ante- and postpartum throm-
boprophylaxis and 4–4.5 % will only be given postpartum
thromboprophylaxis.
4.2.EﬃcacyofLMWHThromboprophylaxis. Withoutthrom-
boprophylaxis, VTE recurs during pregnancy in about 10%Advances in Hematology 5
Table 5: LMWH dose.
Body weight∗
(Kg)
Dalteparin
s.c. U/24h
Tinzaparin
s.c. U/24h
Enoxaparin
mg/24h
Risk score = 2t o4 ∗∗∗
“Normal-dose” thromboprophylaxis <90 5000 4500 40
>90 7500∗∗ 75 U/kg∗∗ 60∗∗
“Very high risk” of VTE∗∗∗∗
<50 2500 × 2∗∗ 20 × 2∗∗
“High-dose” thromboprophylaxis 50–90 5000 × 2∗∗ 175 U/kg∗∗ 40 × 2∗∗
>90 7500 × 2∗∗ 60 × 2∗∗
∗I n i t i a lm a t e r n a lw e i g h ta tt h ea n t e n a t a lc a r eu n i t .
∗∗Initial doses.
∗∗∗Maximum score is 4.
∗∗∗∗measurable anti-FXa activity during the whole day, that is, >0.1U/mL plasma before next dose.
(5% during pregnancy and 5% postpartum) among women
with a prior VTE [18]. Thromboprophylaxis according to
ourguidelines prevents88% ofVTE in women with one pre-
vious episode [18]. However, these women are still at a six-
fold increased risk of both ante- and postpartum VTE [18].
The highest risk is during the post-treatment period, 43–100
days after delivery and termination of thromboprophylaxis
[18]. During the postpartum period, there are many women
without VTE history at the same risk as those with prior
VTE during the antepartum period. Theoretically, the risk
score should be able to reduce the number of postpartum
pulmonary embolisms by two thirds [19]. Since two thirds
of lethal pulmonary embolisms occur postpartum and 1/6
of maternal mortality is caused by pulmonary embolism, the
risk of maternal mortality may theoretically be lowered by
1/12 if the algorithm is followed [19].
Increased maternal age is an established risk factor for
VTE. A ﬁve-fold increased risk is more associated with ma-
ternal age >40 than with the commonly quoted age of >35
[1]. Regarding thrombophilias, we adapted the algorithm
accordingtopracticeinSweden.ProteinCandproteinSdeﬁ-
ciencies were given 2 points each. Almost all women with
thrombophilia, but without history of VTE, were tested
because of family history of VTE (deﬁned as ﬁrst-degree
relative(s) with onset before age 60), yielding a risk score 2+
1 = 3.Theywouldusuallyberecommendedatleastsixweeks
of postpartum thromboprophylaxis. Homozygous FVL was
given 3 risk points and these women would always be
recommended at least six weeks of postpartum thrombopro-
phylaxis.
5.Cost-Effectiveness
Following the guidelines has been shown to be cost-eﬀective,
especially when it comesto postpartum thromboprophylaxis
forthosewithtwoand threerisk points,forwhomthecostof
thromboprophylaxis is between 25% and 50% of the cost of
thrombotic complications [19]. It is important to remember
that the cost-eﬀectiveness data is only valid if the guidelines
are followed strictly.
5.1. Lifestyle Advice. Fertile women with history ofVTE have
an approximately 1–3% annual risk of recurrence [18, 20].
All women with prior VTE should be given lifestyle advice.
Regular exercise cutsthe recurrence risk byhalf [21].Exercise
may be recommended in the form of walking briskly for
around 30 minutes a day, in addition to normal everyday
physical activity. Swimming and water aerobics are suitable
right up until birth during uncomplicated pregnancy. The
risk of VTE is 50% higher during the winter months than
the rest of the year [22]. This may be an eﬀect of vitamin D
deﬁciency in a large proportion of the population, especially
during winter [22]. Women with habitual sun exposure are
at 30% lower risk of VTE as compared to those avoiding
sun exposure [22]. Smoking increases the risk of VTE and
smokers should be advised to quit [1, 23]. Women with
BMI <25 are at a 30% lower risk of VTE than overweight
(BMI 25–30) women and at three-fold lower risk than obese
(BMI 30+) women [1, 23]. By maintaining normal weight,
preferablythrough exercise,therisk ofbloodclotsiskeptlow
[1].
5.2. Amendments. In the revised (2011) version of the rec-
ommendations, inﬂammatory bowel disease was included as
ar i s kf a c t o r[ 24, 25] and abruptio placentae was added as a
risk factor postpartum [2, 26]. Presently, profuse blood loss
and placenta previa are being assessed as potential major risk
factors. In the prior version of the guidelines, women with a
provoked VTE after a temporary situation, such as orthope-
dic surgery, initiated their prophylaxis at 20 weeks gestation.
However, after several recurrences before 20 weeks, we con-
sidered that the diﬀerence in risk between women suﬀering
a VTE after a temporary and a permanent risk factor was
not suﬃcient to lead to diﬀering clinical management. All
women with prior VTE are recommended thromboprophy-
laxis from early pregnancy, which also makes the guidelines
easier to follow.
We conclude that the Swedish guidelines for obstetric
thromboprophylaxis aid clinicians in providing women at
increased risk of VTE with eﬀective and appropriate throm-
boprophylaxis, thus avoiding both over-and under-treat-
ment.6 Advances in Hematology
ConﬂictofInterests
The authors have no conﬂict of interests.
References
[ 1 ]P .L i n d q v i s t ,B .D a h l b ¨ ack, and K. Mars´ al, “Thrombotic risk
during pregnancy: a population study,” Obstetrics and Gyne-
cology, vol. 94, no. 4, pp. 595–599, 1999.
[ 2 ] A .F .J a c o b s e n ,F .E .S k j e l d e s t a d ,a n dP .M .S a n d s e t ,“ I n c i d e n c e
and risk patterns of venous thromboembolism in pregnancy
and puerperium-a register-based case-control study,” Ameri-
can Journal of Obstetrics and Gynecology, vol. 198, no. 2, pp.
e233–e237, 2008.
[3] M. Knight, “Antenatal pulmonary embolism: risk factors,
management and outcomes,” An International Journal of
Obstetrics & Gynaecology, vol. 115, no. 4, pp. 453–461, 2008.
[4] P. E. Marikand L. A. Plante, “Venousthromboembolic disease
and pregnancy,” The New England Journal of Medicine,v o l .
359, no. 19, pp. 2025–2033, 2008.
[5] S.R osfors,A.N or en,R.Hjertberg,L.P ersson,K.Lillthors,and
S. Torngren, “A 16-year haemodynamic follow-up of women
with pregnancy-related medically treated iliofemoral deep
venous thrombosis,” European Journal of Vascular and Endo-
vascular Surgery, vol. 22, no. 5, pp. 448–455, 2001.
[6] M.D.McColl,J.Ellison,I.A.Greer,R.C.Tait,andI.D.Walker,
“Prevalence of the post-thrombotic syndrome in young
women with previous venous thromboembolism,” British
Journal of Haematology, vol. 108, no. 2, pp. 272–274, 2000.
[ 7 ] C .N e l s o n - P i e r c y ,P .M a c C a l l u m ,a n dL .M a c k i l l o p ,“ R e d u c i n g
the risk of thrombosis and embolism during pregnancy and
thepuerperium,” in RCOG Green-TopGuideline No 37a,R o y al
College of Obstetricians and Gynecologists, 2009.
[ 8 ]S .M .B a t e s ,I .A .G r e e r ,I .P a b i n g e r ,S .S o f a e r ,a n dJ .H i r s h ,
“Venous thromboembolism, thrombophilia, antithrombotic
therapy, and pregnancy: American college of chest physicians
evidence-based clinical practice guidelines,” Chest, vol. 133,
no. 6, pp. S844–S886, 2008.
[9] Y. Dargaud, L. Rugeri, M. C. Vergnes et al., “A risk score for
the management of pregnant women with increased risk of
venous thromboembolism: a multicentre prospective study,”
British Journal of Haematology, vol. 145, no. 6, pp. 825–835,
2009.
[10] C. Chauleur, S. Quenet, M. N. Varlet et al., “Feasibility of
an easy-to-use risk score in the prevention of venous throm-
boembolism andplacentalvascularcomplicationsinpregnant
women: a prospective cohort of 2736 women,” Thrombosis
Research, vol. 122, no. 4, pp. 478–484, 2008.
[11] P.G.Lindqvist,M.Kublikas,andB.Dahlb¨ ack,“Individual risk
assessment of thrombosis in pregnancy,” Acta Obstetricia et
Gynecologica Scandinavica, vol. 81, no. 5, pp. 412–416, 2002.
[12] Hem-ARG, Hemostasrubbningar Inom Obstetrik och Gynek-
ologi, Arbets och Referensgruppen f¨ or Hemostasrubbningar,
Stockholm,Sweden, 2004.
[13] H. Salonen Ros, P. Lichtenstein, R. Bellocco, G. Petersson, and
S. Cnattingius, “Increased risks of circulatory diseases in late
pregnancy and puerperium,” Epidemiology,v o l .1 2 ,n o .4 ,p p .
456–460, 2001.
[14] M. Blomb¨ ack, K. Bremme, M. Hellgren, and H. Lindberg, “A
pharmacokinetic study of dalteparin (Fragmin
￿)d u r i n gl a t e
pregnancy,” Blood Coagulation and Fibrinolysis,v o l .9 ,n o .4 ,
pp. 343–350, 1998.
[15] L. A. Norris, J. Bonnar,M. P. Smith,P. J.Steer, and G. Savidge,
“Lowmolecular weight heparin (tinzaparin)therapy for mod-
erate risk thromboprophylaxis during pregnancy. A pharma-
cokinetic study,” Thrombosis and Haemostasis, vol. 92, no. 4,
pp. 791–796, 2004.
[16] C.Brooks,J.M.Rutherford,J.Gould,M.M.Ramsay,andD.K.
James,“Warfarindosageinpostpartumwomen:acase-control
study,” An International Journal of Obstetrics & Gynaecology,
vol. 109, no. 2, pp. 187–190, 2002.
[17] P. G. Lindqvist, P. Olofsson, and B. Dahlb¨ ack,“Use ofselective
factor V Leiden screening in pregnancy to identify candidates
for anticoagulants,” Obstetrics and Gynecology, vol. 100, no. 2,
pp. 332–336, 2002.
[18] P. G. Lindqvist, K. Bremme, and M. Hellgren, “Eﬃcacy of
obstetric thromboprophylaxis and long-term risk of recur-
rence of venous thromboembolism,” Acta Obstetricia et Gyne-
cologica Scandinavica, vol. 90, no. 6, pp. 648–653, 2011.
[19] P. G.Lindqvist,J.Torsson,A. Almqvist,andO.Bj¨ orgell,“Post-
partum thromboembolism: severe events might be pre-
ventable using a new risk score model,” Vascular Health and
Risk Management, vol. 4, no. 5, pp. 1081–1087, 2008.
[ 2 0 ]S .C .C h r i s t i a n s e n ,W .M .L i j f e r i n g ,F .M .H e l m e r h o r s t ,F .R .
Rosendaal, and S. C. Cannegieter, “Sex diﬀerence in risk of
recurrent venous thrombosis and the risk proﬁle for a second
event,” Journal of Thrombosis and Haemostasis,v o l .8 ,n o .1 0 ,
pp. 2159–2168, 2010.
[21] P. G. Lindqvist, E. Epstein, and H. Olsson, “The relation-
ship between lifestyle factors and venous thromboembolism
among women: a report from the MISS study,” British Journal
of Haematology, vol. 144, no. 2, pp. 234–240, 2009.
[22] P. G. Lindqvist, E. Epstein, andH. Olsson,“Does an active sun
exposure habit lower the risk of venous thrombotic events? A
D-lightful hypothesis,”Journalof ThrombosisandHaemostasis,
vol. 7, no. 4, pp. 605–610, 2009.
[ 2 3 ] A .F .J a c o b s e n ,F .E .S k j e l d e s t a d ,a n dP .M .S a n d s e t ,“ A n t e -a n d
postnatal risk factors of venous thrombosis: a hospital-based
case-control study,” Journal of Thrombosis and Haemostasis,
vol. 6, no. 6, pp. 905–912, 2008.
[24] C. N. Bernstein, J. F. Blanchard, D. S. Houston, and A. Wajda,
“The incidence of deep venous thrombosis and pulmonary
embolism amongpatients with inﬂammatorybowel disease: a
population-based cohort study,” Thrombosis and Haemostasis,
vol. 85, no. 3, pp. 430–434, 2001.
[25] M. J. Grainge, J. West, and T. R. Card, “Venous thromboem-
bolism during active disease and remission in inﬂammatory
bowel disease: a cohort study,” The Lancet, vol. 375, no. 9715,
pp. 657–663, 2010.
[26] M. Prochazka, C. Happach, K. Marsal, B. Dahlb¨ ack, and P.
G. Lindqvist, “Factor V Leiden in pregnancies complicated by
placental abruption,” An International Journal of Obstetrics &
Gynaecology, vol. 110, no. 5, pp. 462–466, 2003.